Drug Type Monoclonal antibody |
Synonyms LM 102, LM102 |
Target |
Action modulators |
Mechanism CLDN18.2 modulators(Claudin 18.2 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 06 Oct 2021 | |
| CLDN18.2 positive Solid Tumors | Phase 2 | China | 06 Oct 2021 | |
| Bile Duct Neoplasms | IND Approval | China | 27 Oct 2022 | |
| Pancreatic Cancer | IND Approval | China | 27 Oct 2022 | |
| Stomach Cancer | IND Approval | China | 27 Oct 2022 | |
| Solid tumor | IND Approval | China | 12 Jun 2021 |






